On the Biotechnology front:
Yesterday medical robot maker Hansen Medical (HNSN) reported its Q4 2010 results. See my Hansen Medical Q4 2010 analyst call summary.
Also Onyx Pharmaceuticals (ONXX) held its call. See Onyx Pharmaceutical Q4 2010 analyst call summary.
Neither company was profitable for the quarter. Onyx is investing its Nexavar profits in more clinical trials for Nexavar and in bringing carfilzomib for multiple myeloma to market. Hansen, after the quarter ended, received a large royalty payment from Philips which should fund its development of its experimental robotic catheter for vascular procedures. Hansen hopes the new vascular robots will receive approval this year. If that happens this $2 stock could be a $20 stock by the end of 2012.
I own both stocks.
See also the company home pages: